ASCO Ovarian Cancer Guidelines, Mammo-50 Breast Cancer Surveillance, and NRG1 Fusion Therapy Advances
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
ASCO Ovarian Cancer Guidelines, Mammo-50 Breast Cancer Surveillance, and NRG1 Fusion Therapy Advances
-
Narrated by:
-
By:
About this listen
In this episode of Curie, Matt breaks down three major updates in oncology. ASCO has released updated guidelines for advanced ovarian cancer, emphasizing primary cytoreductive surgery over neoadjuvant chemotherapy when feasible. The Mammo-50 trial challenges the standard of annual mammographic surveillance for breast cancer survivors over 50, showing that less frequent screening is non-inferior. Finally, the eNRGy trial confirms the efficacy of zenocutuzumab in treating NRG1 fusion-positive cancers, a rare but actionable oncogenic driver in NSCLC and pancreatic cancer. Tune in for expert insights into how these findings are shaping cancer care.
activate_mytile_page_redirect_t1
What listeners say about ASCO Ovarian Cancer Guidelines, Mammo-50 Breast Cancer Surveillance, and NRG1 Fusion Therapy Advances
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.